Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease–Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients

Angelo Karaboyas,Daniel Muenz,Douglas S Fuller,Pooja Desai,Tzu-Chieh Lin,Bruce M Robinson,Sandro Rossetti,Ronald L Pisoni

American Journal of Kidney Diseases（2022）

引用 6|浏览33

暂无评分

摘要

In the 12 months after etelcalcetide initiation, patients had large and sustained reductions in PTH levels. These results support the utility of etelcalcetide as an effective therapy to achieve the KDIGO-recommended guidelines for CKD-MBD markers in HD patients.

查看译文

关键词

Calcimimetics,calcium,chronic kidney disease–mineral and bone disease (CKD-MBD),dialysis facilities,drug discontinuation,end-stage renal disease (ESRD),etelcalcetide,hemodialysis,parathyroid hormone (PTH),phosphate binder,phosphorus,PTH target,secondary hyperparathyroidism (SHPT)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要